

ASX ANNOUNCEMENT

Results of 2019 Annual General Meeting

28 November 2019

Analytica Limited (ASX:ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

Resolution Number	Resolution Name	For resolution	Open votes held by the Chair (for resolution)	Against resolution	Abstain from voting
1	Adoption of the Remuneration Report	244,454,843 81.67%	28,418,796 9.49%	26,457,161 8.84%	447,425
2	Re-election of Mr Ross Mangelsdorf as a Director	1,596,719,072 98.04%	28,418,796 1.74%	3,569,870 0.22%	22,800,624
4	Approval of Enhanced Placement Capacity - Special Resolution	1,595,828,961 97.98%	28,418,796 1.74%	4,484,791 0.28%	22,775,814

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance.

